Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

und RG7227 (ITMN-191) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently has submitted in support of its NDA file and plans to submit in support of its MAA filing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly fol
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
(Date:9/1/2015)... , Sept. 1, 2015   Alpha Imaging LLC , a ... Cleveland announced today that they have been awarded exclusive ... imaging systems in Michigan.   The new territory supplements Alpha Imaging,s existing ... including Ohio , Indiana , ... Maryland , West Virginia , ...
(Date:9/1/2015)... Taiwan,s GNT Biotech & Medicals ... Taipei on  August 25 th  to ... drug delivery technology that uses nano-scale gold as the ... a joint press conference held by its parent company ... latest edible gold-based food and beverage partners, together with ...
Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5
... NEW DELHI, October 7 DBMS Consulting announced that ... Suite and Oracle E-Business Suite (EBS) for SIRO Clinpharm, ... OHSA offers fully,automated capabilities in management of clinical trial ... After this implementation, SIRO gains ...
... SAN DIEGO and BASKING RIDGE, N.J., Oct. 7 With ... said today from CTIA WIRELESS I.T. & Entertainment 2009® that ... for its Field Force Manager application that helps address the ... become more productive and efficient. , Designed specifically ...
Cached Medicine Technology:DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 3Verizon Wireless Offers Home Health Care Industry Custom Mobile Application To Be More Productive 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... managed, stress created from everyday life changes can lead to very serious, life-altering ... support for coping with stress. Herbal supplement manufacturer MediHerb has coupled ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... to aid colleges and universities across the country in stemming sexual assaults on ... Campus Climate Collaborative (ARC3), a consortium of sexual assault researchers and student affairs ...
(Date:9/1/2015)... London, UK (PRWEB) , ... September 01, 2015 ... ... of a vacuum that creates negative pressure inside a wound to remove exudates, ... market for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The Jerry ... at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over ... raised more than $13.5 million for programs and services designed to support patients and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural ... women for 19 years and found that, among those who had a stroke, people ... report is part of the September 2015 issue of “Natural Insights for Well Being,” ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... national study, patients being treated for a rare ... University Hospital// (NSUH) and Long Island Jewish (LIJ) ... compound, coupled with standard chemotherapy treatments, significantly increases ... acute promyelocytic leukemia, or APL, and participated in ...
... the standard breast cancer therapy drug tamoxifen, to another one ... , Publishing their findings in the online version of The ... Institute, UK, and team, stood for changing treatments tracks to ... as it reduced deaths by 17 percent. ,Their ...
... encouragement to shut those eyes//. ,Scientists from the ... results that may make it worthwhile to have an afternoon ... Trichopoulos, lead researcher, looked at sleep patterns in Mediterranean countries ... Incidence or rates of heart diseases are low in ...
... Calcium and vitamin D supplementation, even over a short time ... bone) in female military// recruits, according to a study. ... of Defense, looked at 5,201 female U.S. Navy recruits during ... Great Lakes Naval Station near Chicago, Ill. ,The ...
... currently underway brings hope of dramatic advances in ... The review reveals that new approaches in breast ... and research on breast cancer vaccines may lead ... treating breast cancer patients. These new tools may ...
... Centre is planning to set up a 200-bed super ... centres with an initial investment of Rs.300 million. ... of the hospital, told IANS: "We are going to ... in Bangladesh with an aim to provide quality and ...
Cached Medicine News:Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2Health News:Mid-day Naps Healthy for Your Heart 2Health News:Calcium, Vitamin D Supplements Reduce Stress Fractures in Military Recruits 2Health News:Emerging Research Heralds New Era of Breast Cancer Management 2Health News:Kolkata's Birla Hospital to Foray into Bangladesh 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: